XBiotech Announces Dismissal of Class Action Lawsuit in Texas
AUSTIN, Texas, 2016-10-11 14:00 CEST (GLOBE NEWSWIRE) --
XBiotech Inc. (NASDAQ:XBIT), developer of next-generation True Human™ therapeutic antibodies, today announced that the U.S. District Court for the Western District of Texas granted the Company’s motion to dismiss in the 2015 securities class action lawsuit brought against the Company and certain of its directors. In a final judgment issued on October 7th, 2016, the Honorable Judge Sam Sparks dismissed the lawsuit with prejudice, meaning the plaintiff is barred from refiling the claim (Case 1:15-CV-1083-SS).
“We are pleased with the expeditious ruling by Judge Sparks in this case,” said XBiotech Associate Counsel, Sarah Schick.
As previously disclosed, the Company and certain of its directors and officers were also named in a class action suit filed in the Superior Court for the State of California, Los Angeles County. On September 20, 2016, the Los Angeles court entered an order staying the California case in deference to the Texas case. Now that the Texas case has been dismissed, the Company intends to seek the dismissal of the California suit.
About True Human™ Therapeutic Antibodies
Unlike previous generations of antibody therapies, XBiotech’s True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visitwww.xbiotech.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Federal Court Grants Motion to Dismiss Assertion of Claims under Section 10(b) of the Securities Exchange Act
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Nasdaq OMX
Barings17.10.2017 16:31 | pressemeddelelse
Barings Supports New Mountain Capital Investment in DRB Systems
Crown Bioscience Inc.17.10.2017 16:14 | pressemeddelelse
Crown Bioscience to Showcase Scientific Expertise in Preclinical Evaluation of Investigational Cancer Compounds
Oxford Immunotec17.10.2017 15:17 | pressemeddelelse
Oxford Immunotec Schedules Third Quarter 2017 Earnings Release and Conference Call for October 31, 2017
IASLC17.10.2017 08:17 | pressemeddelelse
World Conference on Lung Cancer Tuesday Press Conference: Evidence to Support Innovative Lung Cancer Interventions
EPAM Systems, Inc17.10.2017 06:03 | pressemeddelelse
New Era Launches Direct-to-Consumer eCommerce Site Built by EPAM and Powered with SAP Hybris
LogicBio Therapeutics, Inc.16.10.2017 15:01 | pressemeddelelse
LogicBio Therapeutics to Present Preclinical Data at European Society of Gene & Cell Therapy 25th Anniversary Congress in Berlin
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum